Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.4169
-0.0275-6.19%
Post-market: 0.4100-0.0069-1.66%19:52 EDT
Volume:545.82K
Turnover:235.83K
Market Cap:5.69M
PE:-0.11
High:0.4500
Open:0.4400
Low:0.4101
Close:0.4444
52wk High:14.80
52wk Low:0.4101
Shares:13.65M
Float Shares:12.33M
Volume Ratio:0.80
T/O Rate:4.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8023
EPS(LYR):-4.3726
ROE:-730.06%
ROA:-142.94%
PB:-0.18
PE(LYR):-0.10

Loading ...

Press Release: VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

Dow Jones
·
May 11

VolitionRx feline cancer blood test study shows 86% sensitivity at 97% specificity

Reuters
·
May 06

VolitionRX Announces Submission of Manuscript for Nu.q® Vet Cancer Test in Cats

THOMSON REUTERS
·
May 06

VolitionRx detects nucleosomes in sepsis patients using finger-prick lateral flow prototype study

Reuters
·
Apr 29

VolitionRx enacts 1-for-20 reverse stock split via charter amendment

Reuters
·
Apr 29

VolitionRx wins NYSE American approval of compliance plan, avoids immediate delisting

Reuters
·
Apr 23

VolitionRX Announces Acceptance of Compliance Plan by Nyse American

THOMSON REUTERS
·
Apr 23

VolitionRX Cut to Hold From Buy by D. Boral Capital

Dow Jones
·
Apr 20

VolitionRx downgraded to Hold from Buy at D. Boral Capital

TIPRANKS
·
Apr 20

VolitionRx effects 1-for-20 reverse stock split April 28

Reuters
·
Apr 18

VolitionRX Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 03

VolitionRx price target lowered to $1 from $1.50 at H.C. Wainwright

TIPRANKS
·
Apr 03

VolitionRx shareholders approved reverse stock split authorization at special meeting

Reuters
·
Apr 02

VolitionRx publishes corporate presentation outlining Nu.Q licensing-led cancer and sepsis diagnostics strategy

Reuters
·
Apr 01

VolitionRX Q4 EPS $(0.05), Inline, Sales $447.034K Miss $765.167K Estimate

Benzinga Earnings
·
Apr 01

VolitionRx FY25 net loss narrows 14%; revenue rises 40% to $1.7 million

Reuters
·
Apr 01

Press Release: VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Dow Jones
·
Apr 01

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 31

VolitionRX Ltd - Secures €2.0 Mln Non-Dilutive Funding From Belgian Regional Agencies

THOMSON REUTERS
·
Mar 31

Press Release: VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Dow Jones
·
Mar 31